AS-IV [94] exerts an immunostimulatory impact by suppressing the production of IDO mRNA and protein in lung cancer cells, resulting in a decrease in the number of regulatory T lymphocytes and an increase in CTL activity, culminating in an anti-lung cancer effect. Here, IDO1 is linked to lung carcinoma.